Meera Patrawala, MD
Allergy & Immunology · Roswell, GANPI 1609262203
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,000 of the $11,526 with a category attached, or 69.4%. 27 manufacturers reported payments, led by Sanofi at 42.5% of the total. 2025 is the largest year on record at $3,615, more than ten times the $212 reported in 2021.
Across 312 payments — averaging $36.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$5K
- Novartis$1K
- AstraZeneca$1K
- GSK$724
- Takeda Pharmaceuticals U.S.A., Inc.$603
- Regeneron Healthcare Solutions, Inc.$596
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$3,39429%
- Food & beverage$8,00069%
- Education$1311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 43 | $4,896 |
| Novartis | 37 | $1,300 |
| AstraZeneca | 47 | $1,300 |
| GSK | 40 | $724 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $603 |
| Regeneron Healthcare Solutions, Inc. | 24 | $596 |
| Amgen | 16 | $333 |
| CSL Behring | 12 | $324 |
| ARS Pharmaceuticals Operations, Inc. | 15 | $289 |
| Optinose US, Inc. | 8 | $150 |
| Kaleo, Inc. | 8 | $133 |
| Biocryst US Sales Co., LLC | 5 | $118 |
| Grifols USA, LLC | 4 | $97 |
| AbbVie | 5 | $85 |
| Ionis Pharmaceuticals, Inc. | 3 | $73 |
| Genentech USA, Inc. | 3 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $61 |
| Organon | 2 | $57 |
| Cycle Pharmaceuticals Inc | 2 | $55 |
| Covis Pharma GmbH | 2 | $52 |
| Pharming Healthcare, Inc. | 2 | $47 |
| Pfizer | 2 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $40 |
| LEO Pharma Inc. | 2 | $37 |
| Alk-abello, Inc | 1 | $20 |
| Phadia US Inc. | 1 | $16 |
| Genentech, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,526 in reported general payments places this provider in the 70th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HyqviaIgg/Hyaluronidase,recombinant | 36 | $135,563 |
| Dupixent PenDupilumab | 13 | $48,453 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,931 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 12 | $1,118 |
| Azelastine Hcl | 23 | $744 |
| Montelukast Sodium | 11 | $145 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $603 | $135,56336 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Roswell
- Michael BlaissRoswell$1.1M
- Lily HwangRoswell$88K
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
- Robert CartwrightColumbus$169K
- Robert ChrzanowskiColumbus$115K
- Belinda GrahamSmyrna$94K
- Paul RabinowitzAtlanta$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.